Retatrutide vs. Next-Generation Obesity Drugs
Short answer: Retatrutide is the only triple-receptor agonist (GIP/GLP-1/glucagon) in late-stage trials. Its closest competitors — orforglipron, mazdutide, and cagrilintide/semaglutide — use different mechanisms and are at different stages of development. This page compares the pipeline head-to-head on efficacy, mechanism, and timeline.
The Candidates at a Glance
The Next-Generation Obesity Drug Pipeline
The obesity drug pipeline beyond semaglutide and tirzepatide is crowded, but the mechanisms diverge significantly. Retatrutide adds glucagon receptor agonism to the GIP/GLP-1 dual mechanism of tirzepatide, creating a triple-receptor profile that drives greater energy expenditure alongside appetite suppression. Its competitors take different approaches: orforglipron is a small-molecule oral GLP-1 agonist, mazdutide is a GLP-1/glucagon dual agonist, and cagrilintide/semaglutide (CagriSema) combines an amylin analog with a GLP-1 agonist.
No head-to-head trials exist between these compounds. All efficacy comparisons are cross-trial — different patient populations, trial designs, and endpoints — and should be interpreted with caution. The figures below represent the best available published data as of September 2026.
Mechanism Comparison
The mechanism differences between these drugs are clinically meaningful, not just academic. Glucagon receptor agonism — unique to retatrutide and mazdutide among this group — increases hepatic glucose output and energy expenditure, which may explain the greater weight loss seen with triple-receptor agonism. Orforglipron's oral bioavailability addresses a major barrier to GLP-1 adoption. CagriSema's amylin component slows gastric emptying through a distinct pathway, potentially complementing GLP-1 effects.
| Drug | Mechanism | Route | Developer |
|---|---|---|---|
| Retatrutide | GIP / GLP-1 / Glucagon triple agonist | Subcutaneous injection (weekly) | Eli Lilly |
| Orforglipron | GLP-1 receptor agonist (small molecule, oral) | Oral (daily tablet) | Eli Lilly |
| Mazdutide | GLP-1 / Glucagon dual agonist | Subcutaneous injection (weekly) | Innovent / Roche |
| CagriSema | Amylin analog (cagrilintide) + GLP-1 agonist (semaglutide) | Subcutaneous injection (weekly) | Novo Nordisk |
Efficacy: Weight Loss at Maximum Studied Dose
The following figures are drawn from the highest-dose arms of each drug's most advanced published trial. They are not directly comparable — trial populations, durations, and designs differ. Retatrutide's TRIUMPH-1 Phase 3 topline result of 28.3% mean weight loss at 80 weeks (12 mg, announced May 21, 2026) is the highest reported figure in this class to date. Peer-reviewed publication of TRIUMPH-1 is pending.
Cross-trial comparison only. Different populations, durations, and designs. Not equivalent to a head-to-head trial.
Development Timeline and Approval Outlook
Retatrutide and orforglipron are the furthest along in Phase 3 development among the next-generation candidates. Eli Lilly has initiated the TRIUMPH Phase 3 program for retatrutide; Lilly is also running Phase 3 for orforglipron. Mazdutide (Innovent/Roche) has completed Phase 2 and entered Phase 3 in China, with US development less advanced. CagriSema (Novo Nordisk) has Phase 3 data published.
Regulatory submission timelines are speculative for most of these compounds. Retatrutide: Eli Lilly announced plans for a Q1 2027 regulatory submission following TRIUMPH-1 topline results, with approval potentially in 2027–2028 if the application is accepted and reviewed on standard timelines. Orforglipron may follow a similar timeline. Mazdutide's US approval timeline is unclear. CagriSema's Phase 3 results will inform Novo Nordisk's submission strategy.
| Drug | Current phase | Approval outlook |
|---|---|---|
| Retatrutide | Phase 3 (TRIUMPH) | Q1 2027 regulatory submission planned (Lilly announcement) |
| Orforglipron | Phase 3 | Regulatory submission possible 2026–2027 |
| Mazdutide | Phase 3 (China); Phase 2 (US) | US approval timeline unclear; Phase 3 ongoing in China |
| CagriSema | Phase 3 (REDEFINE) | Regulatory submission anticipated 2026 |
Access and Availability
None of these drugs are commercially available in the United States as of September 2026. The only legal way to access any of them is through an authorized clinical trial. For retatrutide specifically, see our guide on finding a legitimate clinical trial.
See also: When will retatrutide be available? and How to find a legitimate clinical trial.
Compare retatrutide to approved drugs
Frequently Asked Questions
How does retatrutide differ from orforglipron?
Retatrutide is a triple-receptor agonist (GIP/GLP-1/glucagon) administered by weekly subcutaneous injection. Orforglipron is a small-molecule oral GLP-1 receptor agonist taken as a daily tablet. Orforglipron's key advantage is oral administration — no injection or refrigeration required. Retatrutide's key advantage is greater weight loss in cross-trial comparison, driven by its triple-receptor mechanism.
What is mazdutide and how does it compare to retatrutide?
Mazdutide (developed by Innovent and Roche) is a GLP-1/glucagon dual agonist — similar to retatrutide but without GIP receptor agonism. Phase 2 data show approximately 14% weight loss at 24 weeks. US development is less advanced than retatrutide. Both drugs use glucagon receptor agonism to increase energy expenditure, which distinguishes them from pure GLP-1 agents.
What is CagriSema and how does it compare to retatrutide?
CagriSema is Novo Nordisk's fixed-ratio combination of cagrilintide (an amylin analog) and semaglutide (a GLP-1 agonist). Phase 3 REDEFINE 1 data showed approximately 22.7% weight loss at 68 weeks — comparable to retatrutide's Phase 2 results. CagriSema uses a different dual mechanism (amylin + GLP-1) rather than triple GIP/GLP-1/glucagon agonism.
Which next-generation obesity drug will be approved first?
As of September 2026, retatrutide is in Phase 3. Lilly has stated that it plans to submit retatrutide for regulatory review in Q1 2027. Orforglipron is also in Phase 3 with regulatory submission possible in 2026–2027. CagriSema's regulatory submission is also anticipated in 2026. Approval timelines are speculative and depend on Phase 3 data readouts, FDA review timelines, and any safety signals that emerge.
Are any of these drugs available now?
No. None of the drugs on this page — retatrutide, orforglipron, mazdutide, or CagriSema — are FDA-approved for obesity as of September 2026. The only legal way to access any of them in the United States is through an authorized clinical trial registered on ClinicalTrials.gov.
Does retatrutide have the highest weight loss of any drug in development?
Retatrutide's Phase 2 result of approximately 24.2% mean weight loss at 48 weeks (12 mg dose) is the highest published figure in this drug class to date. TRIUMPH-1 Phase 3 topline results announced May 21, 2026 showed 28.3% mean weight loss at 80 weeks (12 mg). Cross-trial comparisons are not equivalent to head-to-head trials. CagriSema's Phase 3 result of ~22.7% at 68 weeks is also in the same range.